Vaccinia

This study tested the JYNNEOS smallpox vaccine in 1,600 healthcare workers in the Democratic Republic of the Congo who are at high risk of catching mpox. The goal was to see if the vaccine can prevent mpox infection and is safe to use. Participants received the vaccine and were m…

This trial tests an experimental virus-based therapy called JX-594 (Pexa-Vec) in people with advanced colorectal cancer that has not responded to standard treatments. The virus is designed to infect and kill cancer cells while also stimulating the immune system. It is given alone…

This study tests a cancer-killing virus called JX-594 (Pexa-Vec) in people with advanced liver cancer that cannot be removed by surgery. Participants receive the virus through an IV and then directly into liver tumors, followed by the standard drug sorafenib. The goal is to see i…

This trial investigates whether JX-594 (Pexa-Vec), a virus modified to attack cancer cells and boost the immune system, combined with best supportive care, can help people with advanced liver cancer live longer. The study enrolls adults whose liver cancer has progressed or who co…

This early-phase trial tests a modified virus called JX-594 (Pexa-Vec) in people with advanced colorectal cancer that has not responded to standard treatments. The virus is designed to infect and kill cancer cells while also stimulating the immune system. The main goal is to chec…

This study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth…

This study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…

This early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…

This early-stage trial tested a modified vaccinia virus (VV-GMCSF-Lact) injected directly into tumors of 34 women with recurrent or metastatic breast cancer that no longer responded to standard treatments. The main goal was to check safety and find the highest safe dose. Research…